Peptide receptor radionuclide therapy (PRRT) is a molecular therapy (radioisotope therapy) used for the treatment of cancer associated with neuroendocrine tumors (NETs). In PRRT, peptides (cell targeting peptide) combine with a small amount of radioactive material to produce radiopharmaceutical product called radio peptide. PRRT can be also considered as personalized cancer therapy, as radio peptide can be altered into the unique biologic characteristics of the patient and the molecular properties of the tumor.
Peptide receptor radionuclide therapy (PRRT) consists of the administration of a tumor-targeting radiopharmaceutical into the circulation of a patient. The radiopharmaceutical will bind to a specific peptide receptor leading to tumor-specific binding and retention. The only target that is currently used in clinical practice is the somatostatin receptor (SSTR), which is overexpressed on a range of tumor cells, including neuroendocrine tumors and neural-crest derived tumors. According to National Institute of Health (NIH) academia played an important role in the development of PRRT, which has led to heterogeneous literature over the last two decades, as no standard radiopharmaceutical or regimen has been available for a long time.
Key features of the study:
- This report provides in-depth analysis of the global peptide receptor radionuclide therapy market, and provides market size (US$ million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Peptide Receptor Radionuclide Therapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Novartis AG (Advanced Accelerator Applications, S.A.), ITM Solucin, and Australasian Gastro-Intestinal Trials Group
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The Global Peptide Receptor Radionuclide Therapy Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Peptide Receptor Radionuclide Therapy Market
Detailed Segmentation:
- Global Peptide Receptor Radionuclide Therapy Market, By Drug Type:
- Lutetium (Lu-177)-based
- Yttrium-90
- Indium-111
- Others
- Global Peptide Receptor Radionuclide Therapy Market, By Disease Indication:
- Pancreatic - Neuroendocrine Tumor
- Gastrointestinal Tract - Neuroendocrine Tumor
- Others
- Global Peptide Receptor Radionuclide Therapy Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Peptide Receptor Radionuclide Therapy Market, By Region:
- North America
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Novartis AG
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
- ITM Solucin
- Australasian Gastro-Intestinal Trials Group
“*” marked represents similar segmentation in other categories in the respective section.
